Vor Biopharma (VOR) Competitors $0.65 -0.05 (-7.14%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock VOR vs. RNAC, TSVT, AQST, TSHA, ATXS, ATYR, ATAI, CMPS, GLUE, and ARCTShould you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), COMPASS Pathways (CMPS), Monte Rosa Therapeutics (GLUE), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. Vor Biopharma vs. Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA Atai Life Sciences COMPASS Pathways Monte Rosa Therapeutics Arcturus Therapeutics Cartesian Therapeutics (NASDAQ:RNAC) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking. Which has more volatility and risk, RNAC or VOR? Cartesian Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Does the MarketBeat Community believe in RNAC or VOR? Vor Biopharma received 18 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 70.89% of users gave Vor Biopharma an outperform vote. CompanyUnderperformOutperformCartesian TherapeuticsOutperform Votes3895.00% Underperform Votes25.00%Vor BiopharmaOutperform Votes5670.89% Underperform Votes2329.11% Do insiders & institutionals have more ownership in RNAC or VOR? 86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 57.9% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 4.7% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, RNAC or VOR? Vor Biopharma has lower revenue, but higher earnings than Cartesian Therapeutics. Vor Biopharma is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCartesian Therapeutics$38.91M7.04-$219.71M-$52.83-0.20Vor BiopharmaN/AN/AN/A-$1.70-0.38 Is RNAC or VOR more profitable? Vor Biopharma has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Company Net Margins Return on Equity Return on Assets Cartesian Therapeutics-510.72% N/A -6.03% Vor Biopharma N/A N/A N/A Do analysts recommend RNAC or VOR? Cartesian Therapeutics presently has a consensus price target of $42.14, indicating a potential upside of 298.70%. Vor Biopharma has a consensus price target of $8.86, indicating a potential upside of 1,262.64%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Vor Biopharma 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to RNAC or VOR? In the previous week, Cartesian Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 2 mentions for Cartesian Therapeutics and 0 mentions for Vor Biopharma. Cartesian Therapeutics' average media sentiment score of 0.64 beat Vor Biopharma's score of 0.00 indicating that Cartesian Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cartesian Therapeutics Positive Vor Biopharma Neutral SummaryCartesian Therapeutics beats Vor Biopharma on 8 of the 15 factors compared between the two stocks. Remove Ads Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VOR vs. The Competition Export to ExcelMetricVor BiopharmaBiological Products, Except Diagnostic Substances IndustryMedical SectorNYSE ExchangeMarket Cap$81.15M$81.15M$5.29B$18.33BDividend YieldN/AN/A5.11%4.23%P/E Ratio-0.39N/A21.6930.99Price / SalesN/AN/A371.6225.38Price / CashN/AN/A38.1517.53Price / BookN/AN/A6.374.26Net IncomeN/AN/A$3.20B$1.02B7 Day Performance12.46%12.46%1.67%-1.29%1 Month Performance-27.41%-27.41%-9.49%-7.34%1 Year Performance-61.99%-61.99%9.59%1.23% Vor Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VORVor Biopharma1.6546 of 5 stars$0.65-7.1%$8.86+1,262.6%-61.1%$81.15MN/A-0.39140Gap DownRNACCartesian Therapeutics1.7275 of 5 stars$10.11+1.1%$42.14+316.8%-37.0%$261.92M$38.91M-0.1964TSVT2seventy bio2.0748 of 5 stars$4.95flat$6.67+34.7%-0.3%$259.07M$37.86M-2.66440Short Interest ↓High Trading VolumeAQSTAquestive Therapeutics1.7607 of 5 stars$2.62-3.3%$10.57+303.5%-34.8%$259.04M$57.56M-5.82160Gap DownTSHATaysha Gene Therapies2.9789 of 5 stars$1.24+1.6%$6.63+434.3%-52.3%$254.20M$8.33M1.97180Gap DownATXSAstria Therapeutics2.4519 of 5 stars$4.50-3.4%$26.60+491.1%-62.4%$253.95MN/A-2.1530Positive NewsHigh Trading VolumeATYRAtyr PHARMA2.7205 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive NewsATAIAtai Life Sciences2.9139 of 5 stars$1.27-3.1%$10.50+726.8%-32.9%$251.85M$308,000.00-1.5780Positive NewsGap UpCMPSCOMPASS Pathways2.5353 of 5 stars$2.70-0.4%$20.20+648.1%-63.7%$250.22MN/A-1.23120Gap UpGLUEMonte Rosa Therapeutics2.9608 of 5 stars$4.05+2.5%$15.50+282.7%-32.6%$249.12M$75.62M-2.2190Short Interest ↓Positive NewsGap DownARCTArcturus Therapeutics3.0636 of 5 stars$9.09-0.2%$59.20+551.3%-63.9%$246.52M$138.39M-4.09180Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies RNAC Competitors TSVT Competitors AQST Competitors TSHA Competitors ATXS Competitors ATYR Competitors ATAI Competitors CMPS Competitors GLUE Competitors ARCT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:VOR) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VOR Stock Free VOR Stock Alerts